Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)
Patent No. EP4014976 (titled "Aprocitentan For Use In The Treatment Of Hypertension And Related Diseases In Combination With Angiotensin Converting Enzyme Inhibitor (Ace) Or Angiotensin Receptor Blocker (Arb)") was filed by Idorsia Pharmaceuticals on Feb 26, 2018. The application was issued on Sep 4, 2024.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4014976
- Application Number
- EP21202979A
- Filing Date
- Feb 26, 2018
- Status
- Granted And Under Opposition
- Aug 2, 2024
- Publication Date
- Sep 4, 2024
- External Links
- Slate, Register , Google Patents